Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biomarin Pharmaceutical Inc (NASDAQ:BMRN), a global biotechnology company focused on developing and commercializing innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases, has reported an insider sell according to a recent SEC filing.